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ABSTRACT
This qualitative study investigated the attitudes, per-
ceptions, and practices of breast cancer specialists
with reference to the effect of patient age on manage-
ment decisions in breast cancer, and attempted to
identify national consensus on this issue. One hun-
dred thirty-three relevant specialists, including 75
surgeons and 43 oncologists, participated in a virtual
consultation using e-mailed questionnaires and open-
ended discussion documents, culminating in the de-
velopment of proposed consensus statements sent to
participants for validation. A strong consensus was
seen in favor of incorporating minimum standards of
diagnostic services, treatment, and care for older pa-
tients with breast cancer into relevant national guid-
ance, endorsed by professional bodies. Similarly, an
overwhelming majority of participants agreed that
simple, evidence-based protocols or guidelines on
standardizing assessment of biological and chrono-
logical age should be produced by the National Insti-
tute for Health and Clinical Excellence and the
Scottish Medicines Consortium, developed in collab-
oration with specialist oncogeriatricians, and
endorsed by professional bodies. A further recom-
mendation that all breast cancer patient treatment
and diagnostic procedures be undertaken in light of
up-to-date, relevant scientific data met with majority
support. This study was successful in gauging na-
tional specialist opinion regarding the effect of pa-
tientageonmanagementdecisionsinbreastcancerin
the U.K. The Oncologist 2010;15:657–664
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The management of elderly patients with breast cancer is
recognized as an area of increasing concern because of the
diverse state of their general health and the relative lack of
evidence for treatment effect within the chemotherapy set-
ting, compared with substantial data on surgery, radiation,
and tamoxifen use. Breast cancer risk increases with age,
and80%ofcasesoccurinwomen50yearsold,withthe
highest number of cases of breast cancer diagnosed in the
50–64 age group [1– 4].
The aging population is increasing—a 65-year-old
woman in the U.K., for instance, now has an average life
expectancyof19.4years[5].Evidence-basedguidelinesfor
themanagementofolderbreastcancerpatientscurrentlydo
not exist.
Manyclinicaltrialshaveusedarbitraryupperagelimits,
and very few studies included large numbers of old (75
years) or very old (85 years) people [6]. Data from a na-
tionalconsultationonprospectivehumanepidermalgrowth
factor receptor (HER)-2 testing indicated that, of those re-
spondents continuing to undertake HER-2 testing selec-
tively, a small minority included age as a stated criterion
[7].
The present study, a qualitative national consultation
exercise carried out in the U.K. between August 2007 and
November 2008, sought to stimulate discussion on the ef-
fect of patient age on management decisions in breast can-
cer and to identify consensus regarding the issue of
biological and chronological age that could be used to in-
fluence and help develop protocols in line with national
guidance.
MATERIALS AND METHODS
The design and content of the U.K. national consultation
exercise were determined by a multidisciplinary steering
group comprising two breast cancer clinicians, a geriatri-
cian, and a breast cancer charity representative (Fig. 1).
In order to explore all possible underlying issues, an
open-ended, qualitative debate was deemed more valuable
thanaprompted,quantitativesurvey.Jobtypewasrecorded
against all response data, which were otherwise anony-
mized.
Participation was invited via a third-party database of
700breastcancerspecialistsprovidingcomprehensivecov-
erage of all U.K. cancer networks. The database was ob-
tained through an independent commercial list hire
company (Dendrite UK) to minimize selection bias. Re-
spondents were required to provide an e-mail address to al-
low the consultation to be conducted via e-mail for the
remainderofitsduration.Toincreaseparticipation,adona-
tion to a charity of the respondents’ choice of £50 per par-
ticipant was pledged.
Respondents to the invitation process received a semi-
quantitative baseline questionnaire—partly factual, partly
attitudinal—developed in collaboration with the steering
group and validated in a previous national consultation on
prospectiveHER-2testing[7],toprovideaninitialgaugeof
situation, opinions, and issues.
Feedbackfromthequestionnairewasusedtoinformthe
selection of topics for the key national discussion stage of
the consultation. An open-ended discussion document was
preparedprovidinganarrativeoffindingsfromthebaseline
survey and seeking national participants’ views on the fol-
lowing issues:
1. Whether exclusion from access to optimum care for
older patients with breast cancer is a national situation.
2. What steps are needed to ensure factors preventing op-
timum access to standard treatment for older breast
cancer patients are effectively addressed.
3. What steps are required to reduce the risk to older
breast cancer patients of exclusion from treatments to
make the largest difference to clinical outcome.
4. Howshortfallsintrainingandtimetohandleallaspects
of older patients with breast cancer relevant to their
management can be effectively addressed.
5. Whichcoredisciplinesshouldalwaysberepresentedin
multidisciplinaryteamstoevaluatewhetherelderlypa-
tients with breast cancer are suitable for treatment.
6. Where any differences in protocols between private
sector and National Health Service (NHS) care are
most likely to occur.
7. Which issues restricting recommendation of chemo-
therapy treatment for older breast cancer patients can
be most easily addressed to achieve greatest benefit.
8. How a protocol or guideline to help standardize varia-
tion in responders’ approach to assessing both biolog-
ical and chronological age can best be developed.
Figure 1. Design of consultation.
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tool for use in assessment of elderly patients with
breast cancer.
10. What should be considered best practice when assess-
ing older breast cancer patients’ health status or fitness
for treatment.
Responses to the consultation phase were studied and
analyzed using a categorization technique comprising un-
qualified agreement, agreement, or disagreement response
categories. However, because this was a largely qualitative
exercise, assessment of the feedback involved careful read-
ing of each response to gauge the type and weight of the
opinion, thus facilitating the drafting of three statements
that were offered to the national consultation participants
for validation of consensus. For each consensus statement,
participants were given three options: unqualified agree-
ment, qualified agreement, or disagreement. Those regis-
tering qualified agreement or disagreement were invited to
explain their response, thereby informing modification of
the consensus statement should this prove necessary.
RESULTS
Participants
A total of 195 individuals responded to the initial mailing,
indicating their willingness to participate. Of these, 133
(68%) responded to at least one stage of the process (Table
1). The discussion stage of the consultation’s process fea-
tured open-ended questions and thus required participants
to provide free text responses. Given the labor intensive-
ness of this stage, taking up a significant amount of respon-
dents’ time, there was a lower rate of response to the
discussion document than to the baseline survey. However
many participants contributed at considerable length to the
discussion stage. A breakdown of registrants and respond-
ers showed a weighting toward surgeons versus oncolo-
gists.
Baseline Survey Findings
Responses to the baseline survey (Table 2) were received
from 103 participants, a 53% response rate. Of these re-
spondents, 41% said age discrimination was a “recognized
problem” that needed to be more widely addressed to en-
hance quality of care in older breast cancer patients, with a
minority(4%)believingthiswasa“majorconcern.”Asim-
ilar proportion (36%) felt that age discrimination was a mi-
nor issue, whereas 20% stated it was not an issue at all.
Factors Preventing Access
Most respondents (61%) said patients at the Trust where
theyworkedwere“sometimes”preventedfromgainingop-
timumaccesstostandarddiagnosticandtreatmentservices.
Influencing factors included general health status or fitness
for treatment (100%), level of understanding among health
careprofessionalsofnormalaging(99%),disability(99%),
a dearth of relevant research data (97%), and a lack of un-
derstanding of life expectancy levels (96%).
A minority (3%) felt patients were “commonly” pre-
vented from access to standard treatment at their Trust,
whereas1%ofrespondentsstatedpatientswere“almostin-
variably” prevented from access. Over a third of respon-
dents (35%) said patients were never prevented from
access.
Mostrespondents(92%)statedthatpatientswereatrisk
for exclusion from chemotherapy, whereas 52% said pa-
tients were at risk for not receiving biological therapy and
50% felt they were at risk for exclusion from primary sur-
gery.
Another 42% of all respondents said patients were at
risk for exclusion from axillary node surgery, whereas 41%
cited radiotherapy following breast-conserving surgery.
Overaquarter(26%)statedthatpatientswereatriskfornot
receiving treatment for metastatic breast cancer and 20%
cited lack of biomarker testing. A minority of respondents
felt patients were at risk for being excluded from triple as-
sessment (clinical examination plus mammography/ultra-
sound scan plus fine needle aspiration/core biopsy) (7%),
hormone or endocrine therapies (2%), and steroid receptor
testing (1%).
Evaluation of Older Patients
Most respondents (61%) were confident that they could
evaluate social and emotional dimensions of patients when
making management decisions, although a minority (20%)
felt “fully equipped” to handle all aspects of patients rele-
vant to their management. Of the remainder, 9% said a lack
Table 1. Breakdown of participants (surgeon/oncologist/
pathologist/radiologist breakdown shown in brackets)
Total signing up
to participate 195 (110/65/16/4) 100%
Respondents to
questionnaire
103 (57/34/8/4) 53%
Respondents to
discussion stage
60 (36/19/4/1) 31%
Respondents to
consensus stage
72 (38/31/2/1) 37%
Respondents to any
stage
133 (75/43/11/4) 68%
Respondents to
all stages
29 (17/9/2/1) 15%
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about effectively evaluating social and emotional dimen-
sionsofpatients,whereas9%believedthattherewasalack
of time for them to adequately manage the complexity of
these dimensions and clinical factors.
Three quarters of respondents worked in a multidisci-
plinary team evaluating whether patients were suitable for
treatment. Most teams included a breast surgeon (96%),
clinical oncologist (91%), and specialist nurse (90%). The
majority of teams (62%) included a medical oncologist,
whereas42%includedananesthetist.Ageriatricianwasin-
cluded in 8% of teams.
Differences Between NHS and Private Sector
Mostrespondents(66%)statedthat,intheirexperience,pa-
tients were “usually”—but not always—managed to the
same protocols in the private sector as in the NHS, with
32%perceivingthatprivateandNHSpatientswere“invari-
ably” managed to the same protocols. A minority (1% in
each case) stated that patients were “rarely” or “never”
managed to the same protocols.
Chemotherapy in Older Patients
Factors restricting a recommendation of treatment with
chemotherapy for patients with early-stage disease were:
poor general health or fitness for treatment (cited by 100%
ofrespondents),comorbidity(99%),lackofrelevantdatain
the elderly (97%), and reluctance of carers to suggest che-
motherapy to patients (95%).
Other factors included: a perception of inaccuracy of
“Adjuvant! Online” data for breast cancer in patients aged
70years(94%),negativeperceptionsamongolderpeople
regarding chemotherapy (94%), poor general medical and
geriatric medicine skills among surgeons (93%), the ab-
senceofatrainednursetoadviseontheassessmentofolder
cancer patients (92%), and tumor characteristics associated
with age (81%).
Comorbid Conditions
Other than poor general health, the key factor in assessing
fitness for chemotherapy in patients was comorbidity. Co-
morbidconditionsconsideredbyrespondentswhenmaking
decisionsregardingtreatmentinpatientswereheartdisease
and chronic obstructive pulmonary disease, each cited by
all respondents. Nearly all respondents also cited diabetes
(98%), hypertension (98%), arthritis (98%), renal failure
(98%), stroke (98%), and previous malignancy (96%).
Comorbidity being a frequently used reason to not pro-
vide older women with treatments was seen as a very im-
portant factor. Older women being more likely than
younger women to not want therapy was also cited as an
important issue.
Regardless of comorbidity, respondents’ main areas of
Table 2. Data from preconsultation baseline survey
BCCG preconsultation questionnaire analysis
March 23, 2009
Total %
Q1. Do you feel that older breast cancer patients
(aged 65) are prevented from optimum access
to standard diagnostic and treatment services
at the Trust or area where you work?
n  103
Almost invariably 1 1%
Commonly 3 3%
Sometimes 63 61%
Never 36 35%
Q2. In your experience, to what extent do the
following factors play a part in preventing
optimum access to treatment for older breast
cancer patients?
n  67
Tumor characteristics 61 91%
General health status or fitness for treatment 67 100%
Geographical location 67 100%
Socioeconomic status of patient 66 99%
GP referral patterns 65 97%
Level of understanding, among health care
professionals, of normal aging
66 99%
Dearth of relevant research data 65 97%
Patient ethnicity 66 99%
Views and attitudes of oncologists and breast
surgeons
66 99%
Disability 66 99%
Level of patient knowledge/education 64 96%
Level of social support (career/advocate) 66 99%
Lack of understanding of life expectancy
levels
64 96%
Other 5 8%
Q3. In your experience, which of the following
aspects of breast cancer care are older patients
at risk for being excluded from?
n  86
Triple assessment 6 7%
Primary surgery 43 50%
Axillary node surgery 37 43%
Radiotherapy following breast-conserving
surgery
35 41%
Steroid receptor testing 1 1%
Chemotherapy 79 92%
Hormone therapies 2 2%
Biological therapy 45 53%
Biomarker testing (e.g., HER-2) 17 20%
Treatment for MBC 22 26%
Q4. In your view, to what extent, if at all, is age
discrimination an issue that needs to be
addressed to enhance quality of care in older
breast cancer patients?
n  101
A major issue 4 4%
A recognized problem that needs to be more
widely addressed
41 41%
Only a minor issue 36 36%
Not an issue at all 20 20%
Abbreviations: BCCG, Breast Cancer Consensus Group;
GP, general practitioner; HER-2, human epidermal
growth factor receptor 2; MBC, metastatic breast cancer.
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heart (cited by 89% of respondents), bone marrow (67%),
and kidney (47%). Around a quarter (23%) of respondents
cited neurological toxicity concerns.
Assessment for Treatment
Biological and Chronological Age. Most respondents
(73%) took the biological and chronological age of patients
into account when considering treatment and management.
The majority of respondents (88%) measured frailty to as-
sessbiologicalage,whereas75%measuredcognition;72%
measuredcardiacfunctiontoassessbiologicalage,whereas
a similar proportion (67%) measured respiratory function.
Another41%ofrespondentslookedatdiabetesstatusinas-
sessing biological age.
Another15%ofallrespondentsreportedtheydidnotas-
sess biological age but took general health and functional
factors into account, whereas a similar proportion (12%)
based age-related decisions solely on biological age when
considering treatment and management.
Suitability for Cytotoxic Treatment. Virtually all re-
spondents (97%) assessed patients’ general health status or
fitness for treatment to determine patients’ suitability for
cytotoxic therapy. Most (91%) assessed patients’ prefer-
ence to determine their suitability, whereas a similar pro-
portion (90%) assessed life expectancy. Most respondents
(83%) assessed physical functioning to determine suitabil-
ity for cytotoxic therapy whereas 78% measured psycho-
logical well-being, 72% assessed social support, 70%
determined cognitive function, 70% looked at tumor char-
acteristics associated with age, and 59% assessed nutri-
tional status.
Assessment Tools. Over half of all respondents (51%)
used the American Society of Anesthesiologists physical
status measurement; the same proportion used the Karnof-
sky performance status score and 20% of respondents used
the Mini Mental Exam. A minority of respondents used the
instrumental activities of daily living (IADL) and ADL
(10% in each case), whereas 4% used the Barthel index.
Response from Open-Ended Discussion Stage
Treatment Access
Feedback from the discussion document was received from
60 (31%) participants. Analysis of responses to the discus-
sionstageshowedageneralconsensusthatolderbreastcan-
cer patients were, in certain areas, excluded from optimum
access to standard diagnostic and treatment services, with
most respondents acknowledging this as a national situa-
tion.
Of the minority of respondents who did not agree that
this was a national problem, most suggested that age per se
might not be the issue. The main concern might be comor-
bidity rendering patients unfit for treatment. This sugges-
tion was acknowledged by many of those who agreed that
there was a national problem, but there was a general con-
sensus that even when taking the patient’s age into account
where it has evidence-based relevance, decisions should be
holistic, multidisciplinary, evidence based, and made in
partnership with the patient.
Asked what steps need to be taken to ensure that the
mostimportantissuespreventingaccesstotreatmentforpa-
tients are effectively addressed, most respondents cited a
need for reliable randomized studies in elderly patients to
compare the advantages and disadvantages of treatment. A
quarter of respondents advocated entering elderly patients
into studies to establish the benefit of chemotherapy in this
population and reduce the risk for exclusion.
Half of the respondents cited the risk for patients being
excluded from primary surgery as the most important treat-
ment issue to address, because this would make the largest
difference to clinical outcome. Many of these respondents
suggested that the most important way of reducing this risk
was to ensure the elderly were subject to multidisciplinary
team review.
On the matter of addressing the shortfall in the number
of respondents who felt fully equipped to handle all aspects
of patients relevant to their management, most respondents
advocated integration of elderly care physicians into multi-
disciplinary teams.
Half of all respondents were opposed to geriatricians
participating in multidisciplinary meetings, many be-
lievingitwouldnotbefeasibletoensuretheirattendance
because of a lack of time. A significant minority of re-
spondents favored geriatricians’ participation at such
meetings, whereas among those opposed there was wide
support for their contribution on a case-by-case consul-
tation basis.
Over half of the respondents pointed to a difference in
standards between private and NHS care. Some respon-
dentspointedoutthatmoretreatmentsmaybeofferedinthe
private sector because patients might feel they can demand
therapieswhentheyarepayingandmaybemorepersuasive
iftheyarehighlyeducated,wealthy,orfromahighersocial
class.
Chemotherapy Trials
A strong consensus emerged advocating independent clin-
icaltrialsofchemotherapyinelderlypatients.Askedwhich
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chemotherapy could be easily addressed to achieve the
most benefit to patients, three quarters of the respondents
cited a lack of relevant data in the elderly population.
Assessment for Treatment
A consensus was also evident in favor of a protocol or
guideline to standardize the approach to the assessment of
biological and chronological age. Asked how best this pro-
tocolcouldbedeveloped,somerespondentssaidguidelines
should be evidence based and simple and must be tested to
allow formulation of a standard protocol. Many respon-
dentsadvocatedthehelpofgeriatriciansinthedevelopment
of such guidelines.
Asked what the ideal objective tool for assessing pa-
tients’ health status or fitness for treatment should be, more
thanathirdofrespondentscitedspecificapproachesinclud-
ingcomprehensivegeriatricassessmentandcognitivefunc-
tion and physical condition assessment tools. A significant
minority said more research was needed to make a judg-
ment. Many respondents suggested that this development
should be within the context of clinical trials.
There was no clear consensus on what should be con-
sidered best practice when assessing patients’ health status
or fitness for treatment.
Consensus Stage
After full analysis and consideration of the consultation
stage feedback, we drafted, for national voting, three con-
sensus statements (Table 3) that were felt to accurately re-
flect the weight and breadth of the opinion received.
Voting on these statements (Table 4) showed a clear
consensus to all of statements 1, 2, and 3. Qualifying com-
ments were made by a number of respondents, particularly
to statements 1 and 3.
DISCUSSION
This study highlights the high level of awareness of and in-
terest in the problem of identifying optimal treatment for
older women with early breast cancer, and the level of en-
thusiasm for finding solutions. Two major trials set up to
help find such solutions, the Adjuvant Cytotoxic Chemo-
therapyinOlderWomen(ACTION)[8]andChemotherapy
Adjuvant Studies for Women at Advanced Age trials [9],
Table 3. Draft consensus statements
Consensus statement 1
In order to ensure uniform and optimum access to diagnostic and treatment services, evidence-based minimum standards of
diagnostic services, treatment, and care for older patients with breast cancer should be incorporated into relevant guidance
from the National Institute for Health and Clinical Excellence and the Scottish Medicines Consortium, and endorsed by
professional bodies.
These standards should be used by all health care professionals involved in breast cancer management, and clinical audit
programs should record the proportion of treatments adhering to this guidance in order that all such patients can expect
equal treatment by 2010.
The recommended treatment should be reviewed in the light of new evidence in 2013 as it originates from up-to-date
research and future drug and therapy development.
Consensus statement 2
All breast cancer patient treatment and diagnostic procedures should be undertaken in the light of up-to-date, relevant
scientific data.
Particular organizations such as the National Cancer Research Institute, National Cancer Research Network, Office for
Strategic Coordination of Health Research, individual research bodies such as Wellcome, Medical Research Council,
Cancer Research UK, and the Government’s research and funding priorities should address the issue of how to specifically
aim clinical trials at older women with breast cancer and investigate associated matters, such as removing the upper age
limits for eligibility into clinical trials and taking measures to encourage recruitment by 2013.
Clinical audit programs should record the ages and numbers of patients treated in clinical trials, and radical or palliative
care.
Consensus statement 3
A simple and evidence-based protocol or guideline (on standardizing the approach to assessing both biological and
chronological age of breast cancer patients when considering treatment and management) should be produced by the
National Institute for Health and Clinical Excellence and the Scottish Medicines Consortium, developed in collaboration
with specialist oncogeriatricians, and endorsed by professional bodies.
This protocol should be used by all health care professionals involved in breast cancer management, and clinicians should
be encouraged to use the guideline by linking clinical audit programs that record the proportion of treatments adhering to
this guidance to specific postgraduate activities and integrating them into formal clinical governance arrangements by 2013.
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or otherwise of adjuvant chemotherapy for this age group,
becausethesetrialswereclosedprematurelybecauseoflow
recruitment, indicating that it is not possible to run a place-
bo-controlled chemotherapy trial.
However, a recent U.S. trial showed that i.v. cytotoxic
combination chemotherapy produces superior disease con-
trolwithacceptablesideeffects,comparedwithsimpleoral
chemotherapy in an older population, defined by a lower
agelimitof65years[10].Thattrialdoesstrengthenthecase
for conducting a study, or even a prospective audit, of ad-
juvant chemotherapy in the elderly population with partic-
ular attention to the presentation assessment of patients’
general health and a careful assessment of toxicity and im-
pact on quality of life.
A study based on the closed ACTION randomized con-
trolled trial is currently being designed, which will involve
prospective audit of characteristics of approximately 300
patients 70 years old who are offered chemotherapy at
multiple U.K. centers, and their subsequent tolerance of
chemotherapy.
The Endocrine  Surgical Therapy for Elderly women
withMammarycancertrialhasalsoclosedprematurelyasa
result of slow recruitment, and there are currently no trials
in the European Organization for Research and Treatment
of Cancer, National Cancer Institute, or National Cancer
Research Network portfolios specifically targeting this
population, despite the absence of evidence on which to
base treatment recommendations.
A closer collaboration between oncologists and geri-
atricians, highlighted by many participants in this study,
would ensure that an aging cohort is less likely to be de-
prived of timely and appropriate clinical input from spe-
cialists in both disciplines. Greater opportunities for
older patients to enter into trials would help to provide
much-needed data on the benefits and risks of chemo-
therapy to this group of patients. Although there is little
evidence as to the most appropriate assessment tool to
determine those most likely to benefit from individual
treatment options, this should not discourage the full as-
sessment of physical, psychological, and social needs of
the elderly patient with breast cancer.
Althoughtherewasahighlevelofagreementtostate-
ments 1 and 3, consensus was not absolute, and further
work in these areas needs to be undertaken before these
two proposals can be implemented. The U.K. Medical
Research Council general practice research database is
the world’s largest database of anonymized medical
records from primary care. It appears particularly urgent
toapplythismodelofclinicalauditprogramtorecordthe
treatment of older patients. This national consultation
did not yield any clear consensus on what should be con-
sidered best practice when assessing patients’ health sta-
tus or fitness for treatment. This issue needs to be further
explored in the future.
CONCLUSION
As an action research exercise, this national consultation
was qualitative in nature and did not produce hard data;
further studies are required to robustly quantify national
opinion. However, the valuable qualitative information ob-
tained by this exercise has provided a relatively clear na-
tional snapshot of practices and attitudes with regard to the
effect of patient age on breast cancer management. Evi-
dence-based discussions may be preferable to variably in-
formedopinions;however,thisconsensuswasinformedby
awidepopulationofthosecloselyinvolvedinbreastcancer
management.
Theriskforself-selectioninthistypeofresearchcan-
not be entirely excluded: those more motivated to estab-
lish change in breast cancer management for elderly
patients may have been more likely to participate in the
consultation. However, those who feel that management
of these patients is not an area for concern might equally
take the opportunity to express their opinions, and these
driversmostlikelycounteracteachother.Likewise,theprovi-
sion of a charity donation incentive, while helping to in-
crease the response rate, also served to buffer the risk for self-
selection.
Table 4. Levels of consensus
Consensus response–
statement 1
Consensus response–
statement 2
Consensus response–
statement 3
Total respondents 72 72 72
Unqualified agreement 49 (68%) 61 (85%) 50 (70%)
Agreement 19 (26%) 11 (15%) 19 (26%)
Disagreement 4 (6%) 0 (0%) 3 (4%)
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